Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 cusatuzumab plus azacitidine in Japanese AML or high-risk MDS not eligible for intensive therapy
jRCT2080225102Phase 1Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of cusatuzumab in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (2 arms), sponsored by Janssen Pharmaceutical. Started Feb 2020; status: terminated.
02
Drugs
cusatuzumab
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on jRCT2080225102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225102.